2nd Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

The BETTER Kidney Care Act (not yet introduced) S.3343/H.R. 5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act The Administrations CMMI Model for Kidney Disease - ESRD Treatment Choices Model. Proposed rule/Final for Medicare Advantage program requirements for contract years 2021 and 2022. COVID-19 emergency aid packages and CARES Act CMS Telehealth Waivers Centers for Medicare & Medicaid Services (CMS) final Medicare Advantage (MA) and Part D rule ESRD Seamless Care Organizations (ESCO) Models S. 3548-CARES ACT & future COVID-19 relief packages Milcon-VA Appropriations

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Vice President of the U.S.; SENATE

Bills named: S. 3548 (116th), S. 3343 (116th), H.R. 5534 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.